Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Completed · Phase 4

Conditions studied: Secondary Hyperparathyroidism, End Stage Renal Disease

In brief

The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

Key facts

Study ID

NCT00053547

Run by

Abbott

People needed

28

Starts

2002-01-01

Last updated by the study team

2006-08-02

Who can join

Age: 2 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University Medical Center — Stanford, California, United States
• Miami Children's Hospital — Miami, Florida, United States
• The Children's Hospital of Buffalo — Buffalo, New York, United States
• Texas Children's Hospital — Houston, Texas, United States
• University of Texas at Houston — Houston, Texas, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.